NCT06481228 2026-03-02
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
Clinical Trials
6 trialsNCT06817720 2026-01-14
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07152041 2025-09-03
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT06390306 2025-06-03
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Peking University People's Hospital
Recruiting
NCT06754267 2024-12-31
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05521204 2022-08-30
Olverembatinib for FGFR1-rearranged Neoplasms
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting